Viscosupplementation Costs
Viscosupplementation (hyaluronic acid or “gel” injections) is an FDA-approved treatment for knee osteoarthritis pain. Insurance coverage for this procedure varies significantly depending on your type of insurance. Recent policy changes effective January 1, 2026 have made it more important than ever to verify your individual benefits before scheduling treatment.
Medicare Coverage
Medicare Part B continues to cover viscosupplementation for knee osteoarthritis under Local Coverage Determinations (LCDs). To qualify, patients must meet all of the following criteria:
- Confirmed diagnosis of symptomatic knee osteoarthritis with pain interfering with daily activities
- Radiographic evidence of osteoarthritis (e.g., joint space narrowing, osteophytes)
- Trial and failure of at least 3 months of conservative therapy (physical therapy, exercise, weight management, NSAIDs, acetaminophen)
- Failure of or contraindication to intra-articular corticosteroid injections
Repeat treatment courses are permitted no more frequently than every six months per knee, provided the patient demonstrated a positive clinical response to prior therapy. Medicare Advantage (Part C) plans must cover at least what Original Medicare covers and may offer additional coverage.
Private / Commercial Insurance
Coverage among private insurers has been inconsistent and is trending toward increased restrictions. Key developments as of 2026:
Blue Cross Blue Shield (BCBS)
Multiple BCBS affiliates—including those in Illinois, Texas, New Mexico, and Montana—discontinued benefit coverage for viscosupplementation for most commercial members effective January 1, 2026. Some patients on maintenance injections may continue to receive coverage through the remainder of 2026. Federal Employee Program (FEP) and government program members are generally excluded from this change. BCBS Medicaid managed care plans in Illinois are now following CMS Local Coverage Determination (LCD) criteria for prior authorization. Coverage policies vary by state and plan. Always verify benefits with your specific BCBS affiliate before scheduling.
UnitedHealthcare (UHC)
UnitedHealthcare’s current commercial policy typically excludes most viscosupplementation products from coverage. Products such as Gel-One, GenVisc 850, Hyalgan, Hymovis, Monovisc, Orthovisc, Supartz, Synvisc, Synvisc-One, and others are listed as excluded. Coverage reviews may apply if required by state law or the specific benefit plan. For Medicare Advantage members, UHC follows Part B step therapy programs.
Other Insurers
Coverage varies widely. Some plans cover viscosupplementation with prior authorization and step therapy requirements (e.g., trial of preferred products first). Others classify it as not medically necessary based on the AAOS clinical practice guideline, which does not recommend routine use. Washington State, for example, does not cover viscosupplementation through its workers’ compensation program.
Out-of-Pocket & Self-Pay Costs
Please contact us to discuss out-of-pocket or self-pay costs, as these costs are subject to change.
What You Can Do
- Contact your insurance company and ask specifically about coverage for viscosupplementation or hyaluronic acid injections (CPT code 20610; HCPCS J-codes J7321–J7328).
- Ask about prior authorization requirements and which brands are preferred under your plan.
- Confirm your deductible and coinsurance obligations so you understand expected out-of-pocket costs.
- If your plan has recently changed coverage, ask whether a transition period or appeal process is available.
Disclaimer
This summary is for informational purposes only and does not constitute a guarantee of coverage. Insurance policies change frequently. Always verify benefits directly with your insurance provider before scheduling any procedure. Information is current as of March 2026.
